Literature DB >> 33846856

Does the order of busulfan and cyclophosphamide affect allogeneic stem cell transplantation related liver toxicity?

Keisuke Kidoguchi1,2, Yasutaka Kuniyoshi3,4, Yuki Kataoka3,5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33846856     DOI： 10.1007/s00277-021-04515-x

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  5 in total

1.  Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT.

Authors:  N Cantoni; S Gerull; D Heim; J Halter; C Bucher; A Buser; D A Tsakiris; J Passweg; A Tichelli; M Stern; A Gratwohl
Journal:  Bone Marrow Transplant       Date:  2010-06-14       Impact factor: 5.483

2.  Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy.

Authors:  Pankaj Rajvanshi; Howard M Shulman; Eric L Sievers; George B McDonald
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

3.  Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.

Authors:  Martha Wadleigh; Paul G Richardson; David Zahrieh; Stephanie J Lee; Corey Cutler; Vincent Ho; Edwin P Alyea; Joseph H Antin; Richard M Stone; Robert J Soiffer; Daniel J DeAngelo
Journal:  Blood       Date:  2003-05-08       Impact factor: 22.113

4.  Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality.

Authors:  Jeannine S McCune; Ami Batchelder; H Joachim Deeg; Ted Gooley; Scott Cole; Brian Phillips; H Gary Schoch; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2007-07       Impact factor: 5.742

5.  The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo.

Authors:  Z Hassan; E Hellström-Lindberg; S Alsadi; M Edgren; H Hägglund; M Hassan
Journal:  Bone Marrow Transplant       Date:  2002-08       Impact factor: 5.483
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.